ન્યુરલ અને સ્નાયુબદ્ધ પેશીઓ બંનેની અસરગ્રસ્ત અથવા લાક્ષણિકતા,

neuromuscular's Usage Examples:

neuromuscular blocking agent has an antagonistic effect on the subsequent depolarising block induced by succinylcholine.

the neuromuscular junction through binding the nidogen proteins and is retrogradely transported towards the soma in signaling endosomes.

is a new experimental neuromuscular blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively.

Spinal deformities may be caused by birth defects, fractures, marfan syndrome, neurofibromatosis, neuromuscular diseases, severe injuries, and tumors.

physical actions which includes: balance retraining, gait analysis and transfer training, neuromuscular retraining, orthotics consultations, and aqua therapy.

binding of ACh to muscarinic acetylcholine receptors; such agents do not antagonize the binding at nicotinic acetylcholine receptors at the neuromuscular.

functioning of the muscles, either directly, being pathologies of the voluntary muscle, or indirectly, being pathologies of nerves or neuromuscular junctions.

terminal Schwann cells of ALS mice (SOD1 mutant) express Sema3A at fast-fatigable fiber neuromuscular junctions greater than wild-type mice.

acetylcholine receptor subtype that is found at the neuromuscular junction of skeletal muscles is the nicotinic acetylcholine receptor (nAChR), which is a ligand-gated.

Spinal muscular atrophy with lower extremity predominance 1 (SMALED1) is an extremely rare neuromuscular disorder of infants characterised by severe progressive.

be classified as neuromuscular or musculoskeletal in nature.

electromyography and blood tests; these also distinguish it from myasthenia gravis, a related autoimmune neuromuscular disease.

Malouetine is an aminosteroid neuromuscular blocking agent and antinicotinic alkaloid isolated from Malouetia spp.